



## UNIVERSITÀ DEGLI STUDI DI TORINO

This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and the University of Turin. Changes resulting from the publishing process - such as editing, corrections, structural formatting, and other quality control mechanisms - may not be reflected in this version of the text. The definitive version of the text was subsequently published in

[Clin Microbiol Infect.](#) 2015 Feb;21(2):e11-3. doi: 10.1016/j.cmi.2014.09.012. Epub 2014 Oct 29.

You may download, copy and otherwise use the AAM for non-commercial purposes provided that your license is limited by the following restrictions:

- (1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND license.
- (2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.
- (3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>), [+ *Digital Object Identifier link to the published journal article on Elsevier's ScienceDirect® platform: [doi:10.1016/j.cmi.2014.09.012](https://doi.org/10.1016/j.cmi.2014.09.012)* <http://www.sciencedirect.com/science/article/pii/S1198743X14000482> ]

# A one-year-survey of Carbapenemase-producing *Klebsiella pneumoniae* in Italy:

## Beyond the ICU

Silvia Corcione\*, Andrea Rocchetti<sup>\*\*\*</sup>, Pier Angelo Argentero<sup>\*\*\*</sup>, Roberto Raso<sup>\*\*\*</sup>, Carla Maria Zotti<sup>§\*\*</sup>, Francesco G. De Rosa<sup>\*#</sup>, Valeria Ghisetti<sup>#^\*\*\*</sup>

\*Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy

°Laboratory of Microbiology, SS Antonio, Biagio and C. Arrigo Hospital, Alessandria, Italy

°° Infection Control Unit, Rivoli Hospital, Rivoli (Turin), Italy

°°° Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi-SeREMI, ASL AL, Alessandria, Italy

§Department of Public Health Sciences and Pediatrics, University of Turin, Italy

^Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital Turin, Italy

# The authors equally contributed to this work.

\*\*On behalf of the Working Group on Healthcare Acquired Infection, Regione Piemonte, Torino, Italy

°Corresponding author:

Silvia Corcione, MD (Corresponding Author)

Department of Medical Sciences

Infectious Diseases,

University of Turin, Italy

Ospedale Amedeo di Savoia

Corso Svizzera 164

10149 Torino

tel. +39 011 4393979

fax. +39 011 4393996

email: corcione.silvia@gmail.com

**Key words:** carbapenemase-producing *Klebsiella pneumoniae*, nosocomial infection, infection control, Italy

**Word text count:** 916

**Sir,**

The spread of carbapenemase-producing *Klebsiella pneumoniae* (KPC-Kp) has become a worldwide problem in recent years with a reported fatality rate from 22% to 72% [1]. In Europe, outbreaks of KPC-Kp have been reported in several countries, but data from the EARS-NET surveillance system showed that, until 2009, the proportion of KPC-Kp remained stable in most countries except Greece and Italy where an increase has been reported from 1-2% in 2006-2009 to 15.2% in 2010 and 27% in 2011 [1]. This trend has recently been confirmed by the Micronet sentinel surveillance network and a recent countrywide cross-sectional survey, outlining the epidemic dissemination in Italy of carbapenem-resistant Enterobacteriaceae (CRE), mostly related to the clonal diffusion of type A KPC-Kp of clonal complex 258 [3-4]. More recently, data from Italian local surveillance systems revealed a persistent condition of KPC-Kp endemicity in hospitals from the North area [5]. In this work, we report results of a one-year-based nosocomial survey of KPC in Italy North-West Italy, covering the metropolitan area of Turin (2,297,917 inhabitants with 5 tertiary referral centers). Aims were to focus on KPC epidemiology in hospital wards as well as antibiotic susceptibility patterns in the year 2012.

The regional surveillance program for infection control in Piedmont, Italy North-West depends from the national and the EARS-NET surveillance systems. It is organized as a network involving Public Health Infection Control Units from regional hospitals with a central coordination board. Data collection is yearly made and involves 29 regional Units covering all the area (4,374,000 inhabitants, 620,917 hospital admissions and 4,314,245 hospital days/year) including 8 tertiary referral and 21 secondary care centres, whose mandatory task on a year-base is to report KP and KPC-Kp clinical isolates from any sample (e.g. urine, blood, sputum, tracheal aspirate, bronchoalveolar lavage, injury swab, abdominal drainage fluid) to investigate the local KPC-Kp epidemiology. The data-set referred to the year 2012 was analysed including only non-duplicate clinical isolates and, for each isolate, site of sampling, antibiotic susceptibility pattern and hospital ward. Data referring to KPC-Kp screening from rectal swabs were not included.

Participating laboratories were asked to provide full information on the methods used for KPC-Kp identification (e.g. automated systems) and antibiotic susceptibility. KPC-Kp showing a pattern of multiresistance (MIC for meropenem >0.5 mg/l) were evaluated for carbapenemase production by meropenem plus EDTA and meropenem plus phenylboronic acid using the disk diffusion method. MICs to Colistin, Tigecycline and Gentamicin were confirmed with the E-test (bioMérieux, Marcy l'Etoile, France).

There were 8,179 Kp isolates from different samples and 1,433 isolates were confirmed as KPC-Kp (17.5%). Tertiary hospitals accounted for the highest KPC-Kp absolute number and the highest rate; being in 5/8 significantly higher than the average count (49; 13.4%). According to hospital admissions, average KPC-Kp incidence was 1.9 per 1,000, with peaks in 7/8 tertiary hospitals. Overall, there was a reduction of KPC-Kp incidence per hospital admissions compared to 2011 (average: 3/1,000), which was important in three tertiary centres (ID# 26T, 23T and 24T).

The majority of KPC-Kp were isolated from urine (50%), respiratory samples (22%) and blood (12%). As many as 31% of KPC-Kp were isolated from patients admitted to medical wards followed by those in ICU (15%), emergency department (14%), surgical

wards (13%), and long-term facilities (10%). Sample distribution was different according to wards of admission (**Figure 1**): in medical wards, emergency departments and long term facilities the majority of KPC-Kp were urinary (56%; 85%; 84%; respectively), whilst in ICU there were more isolates from respiratory tract (56%) and blood (16%). Importantly, KPC-Kp positive blood cultures were found at a similar rate in ICU and medical wards (16%).

Antibiotic susceptibility in secondary and tertiary care centres, respectively, ranged from 75%-100% vs. 67%-90% for colistin, 10%-71% vs. 6%-57% for tigecycline, and 50%-100% vs. 30%-55% for gentamicin. Colistin and tigecycline were tested in only 71% and 43% of laboratories, respectively, mainly in tertiary hospitals (**Table 1**).

A rapid dissemination of KPC-Kp has been reported in Italy since 2010 [2] and confirmed in recently published cross-sectional surveys, challenging the health care system for infection control and prevention procedures. This is the first survey in the North-West of Italy, covering a wide geographical area (4,374,000 inhabitants) and confirming KPC-Kp epidemic diffusion. Our results are in line with those reported from national surveillance system (11.9%) and other recent local report (19.4%) [2-3]. Our results showed that the majority of KPC-Kp were isolated in the year 2012 from patients admitted to tertiary referral centres, even if KPC-Kp incidence decreased compared to the year 2011 in these type of hospitals. Tertiary hospitals accounted for the highest absolute number and rate of KPC, but our data definitively show that the KPC-Kp diffusion is also affecting secondary care hospitals, being the incidence of KPC-Kp above the regional average in one third of them, underscoring that these data should be considered when planning infection control strategies. Moreover, our data highlighted a new trend in KPC-Kp infections, affecting more medical wards with a high number of urinary colonization in this setting compared to ICU, where KPC-Kps were isolated mostly from respiratory airways and blood, suggesting that KPC-Kp is no longer a major issue for critically ill patients [11].

In conclusion, encouraging results of this survey confirm a decreasing trend in KPC-Kp mainly in tertiary referral hospitals. However, KPC-Kp is becoming a challenge also for secondary care hospitals as well as medical wards, confirming that continuous surveillance is important and that implementation of infection control measures at both local and regional level is a key issue for success in this advanced phase of the epidemics. Nowadays, the analysis of susceptibility to colistin and tigecycline should be mandatory in laboratory procedures.

## References

1. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2011. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2012.
2. Sisto A, D'Ancona F, Meledandri M, Pantosti A, Micronet network participants et al. Carbapenem non-susceptible *Klebsiella pneumoniae* from Micronet network hospitals, Italy, 2009 to 2012. *Euro Surveill.* 2012;17(33).
3. Giani T, Pini B, Arena F; AMCLI-CRE Survey Participants et al. Epidemic diffusion of KPC carbapenemase-producing *Klebsiella pneumoniae* in Italy: results of the first countrywide survey, 15 May to 30 June 2011. *Euro Surveill.* 2013;18(22).
4. Corbellini S, Caccuri F, Gelmi M et al. Emergence of carbapenem-resistant *Klebsiella pneumoniae* strains producing KPC-3 in Brescia Hospital, Italy. *New Microbiol.* 2014;37(2):177-83.
5. Corcione S, Cardellino CS, Calcagno A, et al. Healthcare-Associated *Klebsiella pneumoniae* carbapenemase Producing *K. pneumoniae* Bloodstream Infection: The Time Has Come. *Clin Infect Dis.* 2014 Jul 15;59(2):321-2

**Table 1.** Percentage of susceptibility to colistin, tigecycline and gentamycin in participant centers.

| <b>Hospital ID</b> | <b>Colistin Susceptibility (%)</b> | <b>Tigecyclin Susceptibility (%)</b> | <b>Gentamycin Susceptibility (%)</b> |
|--------------------|------------------------------------|--------------------------------------|--------------------------------------|
| <b>1</b>           | 100                                | NA                                   | 50                                   |
| <b>3</b>           | 82,3                               | NA                                   | 30                                   |
| <b>4</b>           | 100                                | NA                                   | 50                                   |
| <b>5</b>           | 75                                 | 71                                   | 50                                   |
| <b>6</b>           | 94,6                               | NA                                   | 64,7                                 |
| <b>8</b>           | 91,7                               | 6,8                                  | 30,6                                 |
| <b>12</b>          | NA                                 | NA                                   | 52,5                                 |
| <b>13</b>          | 90                                 | NA                                   | 58,5                                 |
| <b>14</b>          | 51,8                               | 92,3                                 | 33,3                                 |
| <b>15</b>          | 64,3                               | 41,7                                 | 35,7                                 |
| <b>16</b>          | 95                                 | 100                                  | 70                                   |
| <b>18</b>          | NA                                 | NA                                   | 100                                  |
| <b>19</b>          | 100                                | 100                                  | 83,8                                 |
| <b>19</b>          | NA                                 | NA                                   | 53,6                                 |
| <b>20</b>          | 84,6                               | NA                                   | 54                                   |
| <b>22</b>          | 100                                | 100                                  | 14                                   |
| <b>25</b>          | NA                                 | NA                                   | 20                                   |
| <b>17T</b>         | 75                                 | NA                                   | 62,5                                 |
| <b>23T</b>         | 95                                 | NA                                   | 49                                   |
| <b>24T</b>         | 74,2                               | 57,2                                 | 54,5                                 |
| <b>26T</b>         | 67                                 | NA                                   | 20                                   |
| <b>27T</b>         | NA                                 | 96,3                                 | 38                                   |
| <b>28T</b>         | 90                                 | 12,5                                 | 41,7                                 |
| <b>2T</b>          | 98,7                               | 5,5                                  | 55,8                                 |
| <b>9T</b>          | 87,8                               | NA                                   | 46,3                                 |

Susceptibility data were available for 25 out of 28 hospital centers. T= tertiary care centers; NA= not applicable